Amphastar Eyes Sun Pharma Showdown With US Ganirelix Approval
Other ANDA Sponsor Sun Pharma Had Issued Recall Last Year
Executive Summary
Amphastar is celebrating what it says is its fourth injectable peptide product approval from the USFDA with its generic version of Organon’s ganirelix acetate, in the process setting up a rivalry with Sun Pharma and commercial partner Ferring Pharmaceuticals.
You may also be interested in...
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.
Amphastar Receives FDA Approval For Regadenoson Following Solid Q1
Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.
Amphastar Has First US Glucagon Rival
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.